These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24035472)

  • 1. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
    Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
    Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
    Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
    Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
    Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
    Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Gaivão I; Cardoso ML; Colaço A; Santos L; Oliveira P
    J Toxicol Environ Health A; 2012; 75(13-15):788-99. PubMed ID: 22788366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitors in urinary bladder cancer.
    Pinto-Leite R; Arantes-Rodrigues R; Sousa N; Oliveira PA; Santos L
    Tumour Biol; 2016 Sep; 37(9):11541-11551. PubMed ID: 27235118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
    Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
    Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
    Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
    Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
    Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
    Ma Y; Yu WD; Trump DL; Johnson CS
    Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
    Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
    Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
    Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
    J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
    da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
    Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
    Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
    Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
    da Silva GN; de Castro Marcondes JP; de Camargo EA; da Silva Passos Júnior GA; Sakamoto-Hojo ET; Salvadori DM
    Exp Biol Med (Maywood); 2010 Jul; 235(7):814-24. PubMed ID: 20558835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
    Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
    Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer.
    Xiong Q; Liu A; Ren Q; Xue Y; Yu X; Ying Y; Gao H; Tan H; Zhang Z; Li W; Zeng S; Xu C
    Cell Death Dis; 2020 May; 11(5):366. PubMed ID: 32409654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.